## KVUE: Kenvue Inc. - XLP: Consumer Defensive

### Executive Summary

VALUE thesis: PEG 0.87 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-1.7% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($16.55)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Kenvue Stock (KVUE) News, Forecasts and Analysis for December 23, 2025: Deal Math, Legal Headlines, and What Investors Are Watching**
- Source: ts2.tech | 20251223T162604 | Somewhat-Bearish | Relevance: 100%
- Kenvue Inc. (NYSE: KVUE) stock is currently navigating a complex environment characterized by its pending acquisition by Kimberly-Clark, ongoing legal challenges, and regulatory scrutiny. On December 23, 2025, a new talc-related verdict against Johnson & Johnson explicitly included Kenvue, prompting investors to consider increased deal risk. Additionally, a petition to remove Benadryl's active ingredient and the upcoming shareholder vote on January 29, 2026, are key factors influencing the stock's performance and the spread of the merger valuation.

**2. Publicis Media Wins Kenvue's $1.3B Global Business 12/23/2025**
- Source: MediaPost | 20251223T160749 | Bullish | Relevance: 100%
- Publicis Media has won Kenvue's global media business, which is estimated at $1.35 billion annually. Publicis will handle media, commerce, healthcare professional, and technology support, as well as creative and production for the Neutrogena brand. WPP will lead creative and production for all other Kenvue brands.

**3. Kimberly-Clarkâ€™s purchase of Kenvue is a healthy deal for Pennsylvanians | Opinion**
- Source: PennLive.com | 20251223T130749 | Bullish | Relevance: 100%
- Kimberly-Clark's acquisition of Kenvue, which brings together classic brands like Kleenex, BAND-AID, and Neosporin, is seen as a beneficial deal for Pennsylvania. With Kimberly-Clark operating a plant in Chester and Kenvue having facilities in Fort Washington and Lititz, this merger is expected to protect domestic manufacturing jobs, strengthen the combined company's competitiveness against foreign firms, and stimulate further economic investment and job creation in the state. Former Governor Mark Schweiker expresses optimism about the positive real-world impact of such corporate investment on jobs, innovation, and consumer benefits.

**4. Now WPP nabs some of Kenvue alongside Publicis**
- Source: More About Advertising | 20251223T080749 | Somewhat-Bullish | Relevance: 100%
- WPP has secured a significant win by being named one of two agency networks on consumer healthcare company Kenvue's new roster, alongside Publicis. WPP will handle creative and production for most Kenvue brands, excluding Neutrogena, while Publicis takes on media, commerce, and other services, including creative for Neutrogena. This move highlights ongoing momentum for WPP under new CEO Cindy Rose.

**5. Kenvue Taps WPP & Publicis To Manage Global Adv Duties**
- Source: BW Marketing World | 20251223T050749 | Bullish | Relevance: 100%
- Kenvue, which spun off from Johnson & Johnson in 2023, has restructured its global advertising agencies, appointing WPP and Publicis Groupe as global partners after a competitive review. WPP will handle creative and production for all Kenvue brands except Neutrogena, while Publicis Groupe will manage global media, commerce, healthcare, technology services, and creative/production for Neutrogena. This move aims to sharpen Kenvue's brand-building approach and integrate creative, media, and technology for stronger growth.

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 12.2% (+0.0%)
- Blackrock Inc.: 7.6% (-1.9%)
- Price (T.Rowe) Assoc: 6.0% (-31.5%)
- State Street Corpora: 6.0% (-0.2%)
- FMR, LLC: 4.7% (-9.3%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-1.7% 5d) with bearish MACD, trend may be turning.
2. Long-term trend broken: trading 14.4% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.87 indicates undervaluation relative to growth. Forward P/E 15.6x stretched relative to 7% growth. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $33.0B |
| Beta | 0.56 |
| 52W Range | $14.02 - $25.17 |
| Short Interest | 4.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.87 |
| Forward P/E | 15.6 |
| Current P/E | 16.7 |
| YoY Growth | 7.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 1.1% to -0.6% (-1.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.5pp (needs >4.0% for momentum thesis). Below SMA200 (0.86x), long-term trend not supportive. RSI neutral at 58. OFD pattern: +FTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.55% (CS: 47) | Neutral |
| RSI_14 | 57.5 | Neutral |
| MACD Histogram | -0.04 | Bearish |
| vs SMA20 | 1.006x | Above |
| vs SMA50 | 1.055x | Above |
| vs SMA200 | 0.856x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $17.21
- **Stop Loss:** $16.55 (3.8% risk)
- **Target:** $18.53 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 909
- **Position Value:** $15,643.89
- **Portfolio %:** 15.64%
- **Risk Dollars:** $600.00
- **Risk Per Trade:** 0.60%
- **Modifiers:** L1 120% | L2 50% | Combined 0.60x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite supported by year-end positioning. VIX at cycle lows (13.47) and multiple sectors hitting 52-week highs indicate constructive sentiment, though breadth at 57.9% suggests selectivity remains important. Fed pause expectations and stable macro backdrop support risk assets.*

### Earnings

**Next:** 2026-02-05 (Est: $0.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.26 | $0.28 | +5.7% |
| 2025Q2 | $0.28 | $0.29 | +2.2% |
| 2025Q1 | $0.23 | $0.24 | +5.4% |
| 2024Q4 | $0.26 | $0.26 | +1.5% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*